Mark Cutler
Pfizer
38 Papers
66 Citations
Mark Cutler is an academic researcher from Pfizer. The author has contributed to research in topics: Neutralization & Medicine. The author has an hindex of 13, co-authored 25 publications.
Chat about Author
Papers
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie Cristine Kühnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gábor Szabó,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +48 more
TL;DR: BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavalirus disease-19 (COVID-19)1 as mentioned in this paper.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Jianying Liu,Yang Liu,Hongjie Xia,Jing Zou,Scott C. Weaver,Kena A. Swanson,Hui Cai,Mark Cutler,David A. Cooper,Alexander Muik,Kathrin U. Jansen,Ugur Sahin,Xuping Xie,Philip R. Dormitzer,Pei Yong Shi +14 more
TL;DR: The authors showed that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
Jing Zou,Chaitanya Kurhade,Sohil K. Patel,Nicholas Kitchin,Kristin R. Tompkins,Mark Cutler,David A. Cooper,Qi Yang,Huishan Cai,Alexander Muik,Ying Zhang,Dung Yang Lee,Ugur Sahin,Annaliesa S. Anderson,William C. Gruber,Xuping Xie,Kena A. Swanson,Pei Yong Shi +17 more
TL;DR: In this paper , the authors support the use of the current bivalent vaccine and underscore the importance of monitoring real-world effec-tiveness of real world effectiveness.
151
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
Hongjie Xia,Jing Zou,Chaitanya Kurhade,Huishan Cai,Qi Yang,Mark Cutler,David A. Cooper,Alexander Muik,Kathrin U. Jansen,Xuping Xie,Kena A. Swanson,Pei Yong Shi +11 more
TL;DR: In this article , the antibody neutralization against Omicron SARS-CoV-2 after 2 and 3 doses of BNT162b2 was tested and the data support a 3-dose vaccination strategy and provide a glimpse into the durability of the neutralization response against omicron.
96